Rhythm Q1 product rev $37.7M; Phase 3 HO trial meets endpoint with -19.8% BMI reduction

RHYTHM PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$0.81 revenue$32,704,000

Net product revenue $37.7M, up from $26.0M YoY; U.S. $24.5M, ex-U.S. $13.2M.
Net loss $50.8M ($0.81 per share) vs $141.4M ($2.35) YoY; R&D down due to prior-year acquisition cost.
Phase 3 TRANSCEND trial met primary endpoint: -19.8% placebo-adjusted BMI reduction at 52 weeks (p<0.0001); no new safety signals.
Cash and investments $314.5M as of March 31, 2025; cash runway into 2027.
Fiscal 2025 Non-GAAP operating expense guidance $285M-$315M; regulatory submissions for HO in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.